This article was originally published in The Gray Sheet
Executive SummaryGains FDA market go-ahead for its Hybrid Capture II Gonorrhea test for the detection of neisseria gonorrhea DNA in cervical specimens following recent clearance of the firm's Hybrid Capture II CT-ID Chlamydia test. A herpes test is also in development
You may also be interested in...
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.